Additional file 14 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

Additional file 14. CpGs with concordant significant changes in the survival and resistance acquisition signatures and with significant correlation between paired DNA methylation and gene expression profiles. CpGs in single-locus (Additional File 4) and multi-locus (Additional File 7) survival signatures were selected according to three additional criteria: (i) CpG DNA methylation is significantly (adjusted p-value补充文件14。在生存特征与耐药获得特征中呈现一致显著变化，且在配对DNA甲基化与基因表达谱间存在显著相关性的CpG位点（CpG）。针对单基因座（补充文件4）与多基因座（补充文件7）生存特征中的CpG位点，需依据三项额外标准进行筛选：(i) CpG的DNA甲基化具有显著（校正后P值